←
Solid Biosciences675 posts
Solid Biosciences avatar

Solid Biosciences

@Solid_Bio

Solid’s mandate is to improve the lives of patients living with devastating neuromuscular and cardiac diseases. #TogetherWeAreSolid

◷ Joined October 2016▧ 490 Photos and videos
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Nov 17

That’s a wrap on @icar_ataxia! #TeamSolid was proud to join researchers, clinicians, patient advocates and industry experts to drive shared progress and innovation for people living with ataxias, including Friedreich's ataxia (FA). We're committed to advancing our investigational FA program, SGT-212, with the goal of addressing the neurologic, cardiac and systemic manifestations of the disease. #FACommunity #RareDisease

Post attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Nov 6

Next week, we’re joining the scientific, patient advocacy and industry communities at @icar_ataxia to highlight our investigational Friedreich's ataxia (FA) program, SGT-212, and our Phase 1b FALCON clinical trial design. We look forward to engaging with the field on the latest advancements in ataxia research. #FAcommunity #RareDisease

Post attachmentPost attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Oct 26

Today, we announced that the European Commission has granted Orphan designation to SGT-212, our investigational gene therapy for the treatment of Friedreich’s ataxia (FA), and that five patients have now been dosed in our Phase 1b FALCON clinical trial. Read more: investors.solidbio.com/news-…

Post attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Oct 22

Duchenne muscular dystrophy is a rare genetic condition that causes progressive muscle weakness, impacting movement, respiratory health and cardiac function. It is caused by mutations in the dystrophin gene, which leave muscles more vulnerable to damage over time. We're committed to advancing innovative science to address unmet needs for individuals and families living with #Duchenne. Learn more below. #RareDisease

Post attachmentPost attachmentPost attachmentPost attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Oct 20

At #ESGCT2026, we'll share seven presentations spanning our Duchenne program and platform technologies, including POLARIS-101™, our next-generation, engineered myotropic capsid. Read our press release and visit our posters to learn about our work in #Duchenne, POLARIS-101 and our commitment to advancing genetic medicines. investors.solidbio.com/news-…

Post attachmentPost attachmentPost attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Oct 6

Next week, we're attending the 2026 Friedreich's Ataxia Symposium hosted by Friedreich's Ataxia Research Alliance (FARA) and the Friedreich’s Ataxia Center of Excellence at Children’s Hospital of Philadelphia. Matt Harmelink, Neuromuscular Therapeutic Area Head, will join the FA Drug Development Pipeline Panel Discussion to speak about our work in FA and our Phase 1b FALCON clinical trial. Stop by our exhibit table if you're attending, or register to join the panel virtually: curefa.org/get-involved/educ… #FACommunity #RareDisease

0:11
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Oct 5

We recently joined @defeatduchenne's 2026 Family Forum, which focused on fostering education and connection for individuals and families living with Duchenne. We're proud to support initiatives that empower families with knowledge, foster connections and dialogue, and build community. #Duchenne #RareDisease

Post attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Sep 28

We're committed to shaping the future of gene therapy. POLARIS-101™, our proprietary next-generation, muscle-tropic capsid, has potential to transform the safe, efficient and scalable delivery of genetic medicines across neuromuscular and cardiac diseases. With our #SolidInside approach, we're building a suite of technologies available for partnership and out-licensing to help developers accelerate innovation. Learn more below or on our website: solidbio.com/partners/

Post attachmentPost attachmentPost attachmentPost attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Sep 24

At the Annual World Muscle Society Congress, we're presenting six posters across our neuromuscular portfolio highlighting our work in Duchenne, Friedreich's ataxia and our proprietary POLARIS-101™ capsid, which is designed to enable safe and effective gene therapy delivery and has shown encouraging clinical signals in #Duchenne. We look forward to connecting with leading global experts to advance scientific progress in rare neuromuscular diseases. #WMS2026 #SolidInside

Post attachmentPost attachment
Solid Biosciences avatar
Solid Biosciences@Solid_Bio·Sep 23

We look forward to attending the Annual Neuromuscular Study Group Scientific Meeting, where we'll share two posters highlighting our work in #Duchenne, including our POLARIS-101™ capsid and our Phase 1/2 INSPIRE DUCHENNE study. We value opportunities to engage with researchers, clinicians and advocates working to shape the future of patient care. #SolidInside #RareDisease

Post attachment